Head to head

Epitalon vs NAD+

Other

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Not an either/or

Epitalon and NAD+ appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you do have to pick one, let route and schedule decide it — Epitalon is subcutaneous, intramuscular, once daily; NAD+ is subcutaneous, intramuscular, three times a week — because the evidence does not separate them cleanly enough to do it for you.

What you are actually choosing between

Before anything else: the dataset lists Epitalon and NAD+ in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both fall into the catch-all "other" class here, which is a bucket rather than a shared mechanism — Epitalon and NAD+ do not work the same way. What links them is the goal they are reached for, not the biology.

The overlap is longevity. On this site's goal weighting — an editorial priority score, not a measure of effect size — Epitalon rates 4/5 for longevity and NAD+ rates 4/5. Outside that overlap only NAD+ goes further, carrying weight for focus and cognition and metabolic health; Epitalon's declared goals stop at the overlap.

The evidence

Neither has an evidence edge — both sit at the same tier. Epitalon: some human data, but it is small, old, or uncontrolled; the human reports come from one research group and are unreplicated. NAD+: some human data, but it is small, old, or uncontrolled; controlled trials studied oral precursors, not injected NAD+. Anyone telling you one is clearly better supported than the other is going beyond what is published.

How they differ in practice

No half-life is published for either compound in this dataset. That absence is itself information: it means the pharmacokinetics have not been characterized well enough to quote, so both dosing schedules — once daily for Epitalon, three times a week for NAD+ — are convention.

Committed time differs: Epitalon runs 2 weeks, NAD+ runs 4 weeks.

Risk and difficulty

The contraindication lists are not the same: Epitalon flags active malignancy, which NAD+ does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

Epitalon

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin. Human evidence is thin and comes almost entirely from a single Russian research group (Khavinson and colleagues, St Petersburg Institute of Bioregulation and Gerontology); those reports have not been independently replicated outside that group and the longevity and telomerase claims attached to it should be treated as unproven. It is not an approved medicine in the US or EU. Dosing convention is a short pulsed course rather than continuous use: typically 5-10 mg daily for 10-20 days, repeated once or twice a year. The plasma half-life is very short (reported in minutes), so no meaningful hourly figure is listed here. The active-malignancy flag is precautionary, on the theoretical basis of the claimed telomerase activation.

NAD+

A coenzyme, not a peptide. Human evidence for injected NAD+ itself is weak: most controlled trials study oral precursors (nicotinamide riboside, NMN) rather than parenteral NAD+, and the anti-ageing claims attached to it outrun the data. Doses here are large — the range is 25-250 mg with 100 mg typical, so the microgram figures are in the tens and hundreds of thousands (100 mg = 100,000 mcg). NAD+ is also very commonly given intravenously at 250-1000 mg per infusion over 1-4 hours; there is no IV route in this dataset, so subq is listed and IV is noted here instead. IV dosing is not interchangeable with the subq figures above. Subcutaneous administration is notoriously stinging; users typically start at the low end, inject slowly, and dose every other day rather than daily. Circulating NAD+ is cleared and metabolised rapidly, so no meaningful half-life is listed.

Side by side

The numbers

Epitalon compared with NAD+
Attribute	Epitalon	NAD+
Class	Other	Other
Routes	Subcutaneous, Intramuscular	Subcutaneous, Intramuscular
Dose range	5 mg–10 mg (typical 10 mg)	25 mg–250 mg (typical 100 mg)
Frequency	Once daily	Three times a week
Half-life	Not characterized	Not characterized
Cycle length	2 weeks	4 weeks
Experience	Intermediate	Intermediate
Evidence	Limited human data	Limited human data
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Under 18
Side effects	Injection site redness or stinging Drowsiness or vivid dreams in the first few days Headache, usually mild and transient	Marked burning or stinging at the injection site, the most common complaint Flushing, chest tightness or nausea if given too quickly Cramping and a wave of anxiety or restlessness during administration Headache Fatigue for a few hours afterwards

Turn a typical dose into a mark on the syringe: EpitalonNAD+

Goals

Where they overlap, and where they do not

Goal	Epitalon	NAD+
longevity	Epitalon: 4/5	NAD+: 4/5
recovery and sleep	Epitalon: 3/5	NAD+: 2/5
focus and cognitionone only	Epitalon: —	NAD+: 3/5
metabolic healthone only	Epitalon: —	NAD+: 3/5
immune supportone only	Epitalon: 2/5	NAD+: —
neuroprotectionone only	Epitalon: —	NAD+: 2/5
skin and hairone only	Epitalon: 2/5	NAD+: —

They overlap on 2 goals and diverge on 5. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographEpitalonMechanism, protocol, storage, sources.MonographNAD+Mechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.